Posted by: V.V. Bobritskaya, Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine.
Publication: Reproductive Health. Eastern Europe. 2017, Volume 7, No 4.
The data of an analytical review of the effectiveness of the use of micronized progesterone in various clinical situations are presented: from the beginning of the reproductive period to menopause. According to international consensus, vaginal forms of micronized progesterone are defined as the most effective (along with injectable dosage forms) in cases of threatened preterm birth, habitual miscarriage, in assisted reproductive technology programs. Oral and vaginal dosage forms are recommended in the presence of menstrual irregularities, accompanied by luteal phase insufficiency, the menopausal period in the hormone replacement therapy complex. The new generation micronized progesterone Proginorm Gest for vaginal use and Proginorm OVO for oral use, at a dosage of 100 and 200 mg, are optimal drugs that fully comply with the requirements of domestic and international protocols and are successfully used in relevant clinical situations.
Keywords: micronized progesterone, Proginorm Gest, vaginal dosage form, Proginorm OVO, oral dosage form.